Arbutus Biopharma Corp (ABUS) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Arbutus Biopharma Corp  (NASDAQ: ABUS)


Arbutus Biopharma's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Arbutus Biopharma's ROI in the third quarter of 2026?
Arbutus Biopharma Corp achieved a return on average invested assets (ROI) of 121.09 % in its third quarter of 2026, this is above ABUS's average return on investment of -47.14%.
Arbutus Biopharma Corp invested over the 12 months ending in its third quarter of 2026 $182 million

ROI has improved compared to 84.94% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector 13 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 23 to 39.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 80.74 % 66.86 % 17.47 % -24.97 % -17.59 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 98 271 270 88 92
Return On Investment (TTM) 121.09 % 84.94 % 117.2 % -35.89 % -42.07 %
ABUS's Overall Ranking # 39 # 23 # 3626 # 3917 #
Seq. Investment Change TTM 0.79 % 31.4 % 46.91 % -7.1 % -6.95 %
Seq. Net Income Change TTM 43.68 % -4.77 % - - -
Net Income (TTM) in Millions 220 153 161 -34 -42

ABUS Company Profile >> Back to ABUS Roi Comparisons >> See Annual ABUS Return On Investment



Return On Investment ABUS's Ranking
Within: No.
Industry # 5
Sector # 14
Overall # 39

Return On Investment Statistics
High Average Low
119.86 %
-47.14 %
-143.81 %
(Mar 31 2026)   (Jun 30 2020)







Financial Statements
Arbutus Biopharma's III. Quarter Investments $ 98 Millions ABUS's Balance sheet
Arbutus Biopharma's III. Quarter Income $ 59 Millions Quarterly ABUS's Income Statement
ABUS's Income by Division See ABUS's Income by Division


ABUS Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 89 116 106 163 193
Y / Y Investment Growth -23.12 % 9.29 % -34.66 % -15.89 % 51.53 %
Net Income in Millions -34 -70 -73 -69 -76
Y / Y Net Income Growth - - - - -
Annual Return On Investment -37.54 % -60.23 % -68.58 % -42.73 % -39.45 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ABUS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ABUS's Competitors
Subscribers only: Roi for Arbutus Biopharma's Suppliers
Subscribers only: Return On Investment for ABUS's Customers

Other Ratios
ABUS's Roa ABUS's Inventory Turnover Ratio ABUS's Growth Rates ABUS's Dividend Statistics
ABUS's Profitability Ratios ABUS's Asset Turnover Ratio ABUS's Dividend Growth
ABUS's Roe ABUS's Valuation Ratios ABUS's Financial Strength Ratios ABUS's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Vor Biopharma Inc   293.36 %
Indivior Pharmaceuticals Inc   108.22 %
Exelixis Inc   75.01 %
Ironwood Pharmaceuticals inc   68.68 %
Rigel Pharmaceuticals Inc  68.50 %
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %

Date modified: 2026-11-11T05:41:30+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.